Drug Combination Details
| General Information of the Combination (ID: C33998) | |||||
|---|---|---|---|---|---|
| Name | Glycine NP Info | + | Folfox Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Colorectal cancer
[ICD-11: 2B91]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Decreasing Adverse Drug Reaction by This Combination | ||||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | FABP3 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | Human cardiac myocytes | Healthy | Homo sapiens | |||
| In-vivo Model | For a xenograft model, CC531 cells were injected into the right liver lobe of seven-week-old male Wag/Rij rats. | |||||
| Experimental
Result(s) |
Dietary glycine protects the heart against FOLFOX-induced injury during treatment for CRLM. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Dietary Glycine Prevents FOLFOX Chemotherapy-Induced Heart Injury: A Colorectal Cancer Liver Metastasis Treatment Model in Rats. Nutrients. 2020 Aug 28;12(9):2634. | |||
